14/04/2018
M&S Decisions took part in the Annual Meeting of American Association of Cancer Research 2018 where we presented the work “Quantitative modeling as a systematic approach for drug combination evaluation in Immuno-Oncology”.
A mechanistic model describing interactions among host immune cells and tumor cells was developed. The proposed model was used to explore the effects of PD-1 and CTLA-4 immune checkpoint inhibitors, OX40 agonistic ligand and CXCR2 blocking antibody, and their combinations, on tumor microenvironment and tumor growth dynamics in various experimental murine models. The types of synergistic effects which may arise from immuno-oncology drug combinations were categorized across realistic baseline conditions prevailing in the tumor microenvironment (TME).
